Sodium–glucose cotransporter-2 (SGLT2) inhibitors are widely used not only for patients with diabetes mellitus (DM) but also for patients with congestive heart failure (CHF) and chronic kidney disease (CKD) regardless of DM status. The gene discussed is SLC5A2; the disease is diabetes mellitus.